Shop

Kinbet contains the active ingredient Tetrabenazine and is manufactured by Viralian Company. This medication belongs to the class of antidyskinetic agents, used for the treatment of movement disorders caused by excessive dopaminergic activity in the central nervous system.

Kinbet is primarily indicated for the management of chorea associated with Huntington’s disease, as well as other hyperkinetic movement disorders such as severe tics, dystonia, and drug-induced involuntary movements. The drug works by inhibiting dopamine reuptake at nerve terminals, thereby reducing involuntary motor stimulation and improving muscle coordination.

The dosage is usually titrated gradually to achieve the optimal therapeutic effect with minimal side effects. Kinbet should be administered under close medical supervision, particularly in patients with a history of depression or psychiatric disorders, as Tetrabenazine may induce depressive symptoms or drowsiness in some individuals.

Contraindications include active depression, suicidal ideation, severe hepatic impairment, or concurrent use of monoamine oxidase inhibitors (MAOIs).
Common side effects may include drowsiness, insomnia, fatigue, or mild gastrointestinal symptoms.

With its precise formulation by Viralian Group, Kinbet is considered an effective medication for managing neurologically-based movement disorders.